乳腺癌放疗后立即乳房重建与淋巴水肿发生的关系。

IF 6.4 1区 医学 Q1 ONCOLOGY
Soon Woo Hong, Eun-Kyu Kim, Hee-Chul Shin, Jaewon Beom, Jae-Young Lim, Koung Jin Suh, Jee Hyun Kim, Kyubo Kim, In Ah Kim
{"title":"乳腺癌放疗后立即乳房重建与淋巴水肿发生的关系。","authors":"Soon Woo Hong, Eun-Kyu Kim, Hee-Chul Shin, Jaewon Beom, Jae-Young Lim, Koung Jin Suh, Jee Hyun Kim, Kyubo Kim, In Ah Kim","doi":"10.1016/j.ijrobp.2025.05.062","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer-related lymphedema (BCRL) is often challenging to manage, and knowledge of how to prevent it is limited. There are several well-known risk factors, but recent studies have also suggested the potential association of immediate breast reconstruction with lower incidence, albeit with inconclusive results. Thus, we explored the impact of immediate breast reconstruction on lymphedema incidence in breast cancer patients who underwent a mastectomy and adjuvant radiation therapy (RT).</p><p><strong>Methods and materials: </strong>We retrospectively reviewed 440 breast cancer patients who underwent a mastectomy with adjuvant RT from 2012 to 2020. Of these, 229 underwent immediate breast reconstruction (IR group), and 211 underwent no reconstruction (NR group). BCRL events were defined and graded on a scale of 0 to 3 following the International Society of Lymphology (ISL) staging system. After excluding patients who experienced BCRL before radiotherapy (n=30), with propensity score matching, we utilized log-rank analysis and multivariate Cox regression models to identify associated factors. Then, the clinical course of BCRL was explored with flow diagrams.</p><p><strong>Results: </strong>After a median follow-up period of 35 months, 116 patients (26%) developed BCRL, with 74% classified as ISL stage 2-3. 2-year actuarial rate of BCRL was 16.3% for the IR group, and 28.9% for the NR group (p=0.020). In a multivariate Cox regression of propensity score-matched (PSM) cohort (n=180), patients were more likely to develop stage ≥2 BCRL if 15 or more axillary lymph nodes were resected (p=0.035), or intensity-modulated radiotherapy (IMRT) was given (p=0.004). However, immediate breast reconstruction was associated with a lower incidence of BCRL (p=0.022). Regarding patients with initial stage 0 or 1 BCRL, the IR group showed a lower rate of progression during follow-up compared with the NR group (33% vs. 60%).</p><p><strong>Conclusions: </strong>In postmastectomy breast cancer patients, resection of 15 or more axillary lymph nodes, as well as IMRT, were found to be significantly associated with lymphedema occurrence. Notably, immediate breast reconstruction may be associated with a lower incidence of lymphedema.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Relationship of Immediate Breast Reconstruction and the Development of Lymphedema in Breast Cancer Patients with Radiotherapy.\",\"authors\":\"Soon Woo Hong, Eun-Kyu Kim, Hee-Chul Shin, Jaewon Beom, Jae-Young Lim, Koung Jin Suh, Jee Hyun Kim, Kyubo Kim, In Ah Kim\",\"doi\":\"10.1016/j.ijrobp.2025.05.062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Breast cancer-related lymphedema (BCRL) is often challenging to manage, and knowledge of how to prevent it is limited. There are several well-known risk factors, but recent studies have also suggested the potential association of immediate breast reconstruction with lower incidence, albeit with inconclusive results. Thus, we explored the impact of immediate breast reconstruction on lymphedema incidence in breast cancer patients who underwent a mastectomy and adjuvant radiation therapy (RT).</p><p><strong>Methods and materials: </strong>We retrospectively reviewed 440 breast cancer patients who underwent a mastectomy with adjuvant RT from 2012 to 2020. Of these, 229 underwent immediate breast reconstruction (IR group), and 211 underwent no reconstruction (NR group). BCRL events were defined and graded on a scale of 0 to 3 following the International Society of Lymphology (ISL) staging system. After excluding patients who experienced BCRL before radiotherapy (n=30), with propensity score matching, we utilized log-rank analysis and multivariate Cox regression models to identify associated factors. Then, the clinical course of BCRL was explored with flow diagrams.</p><p><strong>Results: </strong>After a median follow-up period of 35 months, 116 patients (26%) developed BCRL, with 74% classified as ISL stage 2-3. 2-year actuarial rate of BCRL was 16.3% for the IR group, and 28.9% for the NR group (p=0.020). In a multivariate Cox regression of propensity score-matched (PSM) cohort (n=180), patients were more likely to develop stage ≥2 BCRL if 15 or more axillary lymph nodes were resected (p=0.035), or intensity-modulated radiotherapy (IMRT) was given (p=0.004). However, immediate breast reconstruction was associated with a lower incidence of BCRL (p=0.022). Regarding patients with initial stage 0 or 1 BCRL, the IR group showed a lower rate of progression during follow-up compared with the NR group (33% vs. 60%).</p><p><strong>Conclusions: </strong>In postmastectomy breast cancer patients, resection of 15 or more axillary lymph nodes, as well as IMRT, were found to be significantly associated with lymphedema occurrence. Notably, immediate breast reconstruction may be associated with a lower incidence of lymphedema.</p>\",\"PeriodicalId\":14215,\"journal\":{\"name\":\"International Journal of Radiation Oncology Biology Physics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.4000,\"publicationDate\":\"2025-05-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Radiation Oncology Biology Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijrobp.2025.05.062\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2025.05.062","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介:乳腺癌相关淋巴水肿(BCRL)往往是具有挑战性的管理,知识如何预防它是有限的。有几个众所周知的危险因素,但最近的研究也表明,立即乳房重建与发病率较低的潜在联系,尽管结果不确定。因此,我们探讨了即时乳房重建对接受乳房切除术和辅助放射治疗(RT)的乳腺癌患者淋巴水肿发生率的影响。方法和材料:我们回顾性分析了2012年至2020年440例接受乳房切除术和辅助放疗的乳腺癌患者。其中,229人接受了立即乳房重建(IR组),211人没有接受乳房重建(NR组)。根据国际淋巴学会(ISL)分期系统对BCRL事件进行定义和分级,分为0到3级。在排除放疗前经历过BCRL的患者(n=30)后,采用倾向评分匹配,我们使用log-rank分析和多变量Cox回归模型来确定相关因素。然后用流程图对BCRL的临床过程进行探讨。结果:中位随访35个月后,116例患者(26%)发展为BCRL,其中74%为ISL 2-3期。IR组2年BCRL精算率为16.3%,NR组为28.9% (p=0.020)。在倾向评分匹配(PSM)队列(n=180)的多变量Cox回归中,如果切除15个或更多腋窝淋巴结(p=0.035)或给予调强放疗(IMRT) (p=0.004),患者更有可能发展为≥2期BCRL。然而,立即乳房重建与较低的BCRL发生率相关(p=0.022)。对于初始BCRL为0期或1期的患者,IR组在随访期间的进展率低于NR组(33%对60%)。结论:在乳房切除术后的乳腺癌患者中,切除15个或更多腋窝淋巴结以及IMRT与淋巴水肿的发生有显著相关性。值得注意的是,立即乳房重建可能与淋巴水肿发生率较低有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Relationship of Immediate Breast Reconstruction and the Development of Lymphedema in Breast Cancer Patients with Radiotherapy.

Introduction: Breast cancer-related lymphedema (BCRL) is often challenging to manage, and knowledge of how to prevent it is limited. There are several well-known risk factors, but recent studies have also suggested the potential association of immediate breast reconstruction with lower incidence, albeit with inconclusive results. Thus, we explored the impact of immediate breast reconstruction on lymphedema incidence in breast cancer patients who underwent a mastectomy and adjuvant radiation therapy (RT).

Methods and materials: We retrospectively reviewed 440 breast cancer patients who underwent a mastectomy with adjuvant RT from 2012 to 2020. Of these, 229 underwent immediate breast reconstruction (IR group), and 211 underwent no reconstruction (NR group). BCRL events were defined and graded on a scale of 0 to 3 following the International Society of Lymphology (ISL) staging system. After excluding patients who experienced BCRL before radiotherapy (n=30), with propensity score matching, we utilized log-rank analysis and multivariate Cox regression models to identify associated factors. Then, the clinical course of BCRL was explored with flow diagrams.

Results: After a median follow-up period of 35 months, 116 patients (26%) developed BCRL, with 74% classified as ISL stage 2-3. 2-year actuarial rate of BCRL was 16.3% for the IR group, and 28.9% for the NR group (p=0.020). In a multivariate Cox regression of propensity score-matched (PSM) cohort (n=180), patients were more likely to develop stage ≥2 BCRL if 15 or more axillary lymph nodes were resected (p=0.035), or intensity-modulated radiotherapy (IMRT) was given (p=0.004). However, immediate breast reconstruction was associated with a lower incidence of BCRL (p=0.022). Regarding patients with initial stage 0 or 1 BCRL, the IR group showed a lower rate of progression during follow-up compared with the NR group (33% vs. 60%).

Conclusions: In postmastectomy breast cancer patients, resection of 15 or more axillary lymph nodes, as well as IMRT, were found to be significantly associated with lymphedema occurrence. Notably, immediate breast reconstruction may be associated with a lower incidence of lymphedema.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.00
自引率
7.10%
发文量
2538
审稿时长
6.6 weeks
期刊介绍: International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field. This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信